Immunotherapy drug aims to keep adrenocortical cancer at bay
NCT ID NCT07085572
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether the immunotherapy drug cemiplimab can delay or prevent cancer progression in people with advanced adrenocortical cancer whose disease has been stabilized by initial chemotherapy. About 31 participants will receive cemiplimab every three weeks. The main goal is to see how many remain progression-free after six months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cemiplimab (a cancer immunotherapy drug)
What this could lead to
If it works, this could offer a new maintenance option to delay cancer progression in patients with advanced adrenocortical cancer.
What could go wrong
This is a small, early-phase trial with only 31 participants, so results may not apply broadly. The drug may not effectively prevent progression and could cause immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADRENAL CORTICAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
S.C. Oncologia - ASST Spedali Civili di Brescia
RECRUITINGBrescia, Brescia, 25123, Italy